Japan cardiology market is projected to grow significantly at a CAGR of around 6.5% during the forecast period. There are various factors that provide substatial growth ot the Japan cardiology market including availability of developed healthcare infrastructure and technological advancement in cardiology device technologies in the country. Japan is a technologically sound nation which is equipped with innovative methods for various heart surgeries. Government of Japan initiated various awareness programs through Japanese Society for Cardiovascular Surgery. The awareness level for heart diseases are increasing in Japan and the adoption of surgeries are also increasing at modest rate. Various universities, R&D institutes, hospitals and clinics are exploring cardiology surgeries through R&D to come up with innovative approach and devices for cardiology surgeries.
The market is segmented on the basis of device type, drug type, mechanism, and surgeries type. Based on Device type, the market is segregated angioplasty, cardiovascular stents, cardiovascular catheters, cardiac rhythm management, cardiovascular assistive devices. Angioplasty and vascular stenting are widely adopted procedures in the cardiology market and have a considerable market share. Based on the drug type, the market is segmented into antithrombotic drugs, antidyslipidemic drugs, antihypertensive drugs, and anti-stroke drugs. On the basis of surgeries type, the market is classified into coronary artery bypass grafting, transmyocardial laser revascularization, heart valve repair, arrhythmia treatment, aneurysm repair, and heart transplant.
The companies which are contributing to the growth of the Japan cardiology market include Abbott Laboratories, Terumo Corp., Daiichi Sankyo Co. Ltd., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Boston Scientific Corp., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.
Research Methodology
The market study of the Japan cardiology market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include
The report is intended for medical device companies, pharmaceuticals companies, research institutes, hospitals, and government organizations for the overall market and competitive analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
The Report Covers
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Japan Cardiology Market by Device Type
5.1.1. Angioplasty
5.1.2. Cardiovascular stents
5.1.3. Cardiovascular catheters
5.1.4. Cardiac rhythm management
5.1.5. Cardiovascular assistive devices
5.2. Japan Cardiology Market by Drug Type
5.2.1. Antithrombotic drugs
5.2.2. Antidyslipidemic drugs
5.2.3. Antihypertensive drugs
5.2.4. Anti-stroke drugs
5.3. Japan Cardiology Market by Mechanism
5.3.1. Beta blockers
5.3.2. Beta agonists
5.3.3. Alpha blockers
5.3.4. Alpha agonists
5.3.5. Sodium channel blockers
5.3.6. Calcium channel blockers
5.3.7. Vasodilators
5.3.8. Renin inhibitors
5.3.9. Angiotensin receptor blockers
5.3.10. Diuretics
5.3.11. Thrombolytics
5.4. Japan Cardiology Market by Surgeries Type
5.4.1. Coronary artery bypass grafting
5.4.2. Transmyocardial laser revascularization
5.4.3. Heart valve repair
5.4.4. Arrhythmia treatment
5.4.5. Aneurysm repair
5.4.6. Heart transplant
6. Company Profiles
6.1. Abbott Laboratories
6.2. Terumo Corp.
6.3. Daiichi Sankyo Co. Ltd.
6.4. Otsuka Pharmaceutical Co., Ltd.
6.5. Takeda Pharmaceutical Co., Ltd.
6.6. Boston Scientific Corp.
6.7. General Electric Co.
6.8. Japan Lifeline Co., Ltd.
6.9. Pfizer Inc.
6.10. F. Hoffmann-La Roche Ltd.
1. JAPAN CARDIOLOGY MARKET RESEARCH AND ANALYSIS BY DEVICE TYPE, 2018-2025 ($ MILLION)
2. JAPAN CARDIOLOGY MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2018-2025 ($ MILLION)
3. JAPAN CARDIOLOGY MARKET RESEARCH AND ANALYSIS BY MECHANISM, 2018-2025 ($ MILLION)
4. JAPAN CARDIOLOGY MARKET RESEARCH AND ANALYSIS BY SURGERIES TYPE, 2018-2025 ($ MILLION)
1. JAPAN CARDIOLOGY MARKET SHARE BY DEVICE TYPE, 2018 VS 2025 (%)
2. JAPAN CARDIOLOGY MARKET SHARE BY DRUG TYPE, 2018 VS 2025 (%)
3. JAPAN CARDIOLOGY MARKET SHARE BY MECHANISM, 2018 VS 2025 (%)
4. JAPAN CARDIOLOGY MARKET SHARE BY SURGERIES TYPE, 2018 VS 2025 (%)